Alonzo Autrey
Managing Director
DVA Mexicana
/
View from the Top

Solutions in a Third of the Standard Time

Thu, 09/07/2017 - 17:10

Q: What value is DVA Mexicana bringing to the healthcare sector?

A: EasyCoat, our own brand, includes the manufacturing of pharmaceutical film coatings for medicines. We are focused on understanding trends and the direction of the market so we can build strong relationships with our clients, offer an integral solution and launch it to market as quickly as possible. If a client wants to launch a medicine that has a soon-to-be expired patent, we look at how to get supply sources that could be validated by COFEPRIS to launch it in the shortest time possible. The diversity of our excipients and our film coating EasyCoat are key strengths for our pharma division. These allow us to develop solutions in short periods of time, about a third of the market standard. Q: What is the profile of DVA Mexicana’s ideal client? A: As most development does not occur in Mexico but in the US, some ingredients cannot be changed, so the majority of our clients are those companies that do carry out local development, often generics companies. Some are from the US but also from India and Israel, among others. For these types of companies, 50 percent of their sales go to the government through the public tenders. Generics have much future potential in Mexico. The generics market continues to grow expansively, at double digits.

Q: What benefits is DVA and its clients deriving from the changes in COFEPRIS regulations?

A: COFEPRIS decided that all manufacturers must have a GMP from an authorized source, such as the US, Brazil or Mexico. It also mandated the separation of high-risk and low-risk products, which means that low-risk products require a local GMP, whereas high-risk products have to be certified by another source. This makes the process more agile and opens more opportunities for manufacturers.

Q: What nutritional products does DVA Mexicana offer?

A: We are focused on dairy products, bakery, meat and beverages. We have a plant in Atitalaquia, Hidalgo, and a laboratory where we elaborate functional solutions such as Appenmix to optimize our clients’ product quality production cost and performance. For example, we reformulate products to prevent syneresis, which occurs when packaged products like beverages, ham and cheese start losing water and consumers find water accumulated when they open the package. We also provide the vegetable proteins raw burgers need to stay consistent when the consumer cooks them. For those clients that manufacture nutritional beverages and supplements, we create a functional mix that aims to make the product better. With this mix, the client can obtain the right amount of proteins, vitamins and flavor.

Q: What is your main focus: increasing the volume of production or entering new areas?

A: We are focusing on higher added-value activities for our customers. We do expect COFEPRIS to fully regulate the excipient business in the same way as others, which means having a plant with a GMP is an advantage and provides us with opportunities to export in the near future. Having a plant that is up to international standards is opening the door for us. Thankfully, all the transnationals that are in Mexico buy high-quality products from the US and so we can compete. We must also comply with the requirements of our foreign clients because many export to the US and so must follow FDA regulations. Today, the Mexican industry is facing a challenge: how to become more efficient in logistics and productivity when buying ingredients.

When we began to see the dollar appreciating against the peso, the pressure on clients of pharmaceutical products and food increased because everything is sold in pesos. The food sector has been challenging, but we have seen many opportunities. We have decided to invest in a functional blends manufacturing plant to continue to expand in the higher added-value solutions.